Core Viewpoint - NetraMark Holdings Inc. and Pentara Corporation have entered into a partnership to co-brand and launch a novel site intelligence tool aimed at enhancing clinical trial integrity through advanced AI-driven anomaly detection [1][2]. Group 1: Partnership Details - The collaboration will focus on a site intelligence tool that utilizes information-theoretic variability and other metrics to derive a Paradox Risk score for anomaly detection at the participant level [2]. - This tool aims to identify anomalous participants and assess site-level irregularities using only pre-randomization data, addressing potential data integrity issues that could affect study conclusions [2][6]. Group 2: Company Profiles - NetraMark is positioned as a leader in Generative AI and Machine Learning solutions for the pharmaceutical industry, utilizing a novel algorithm to analyze patient data effectively [7]. - Pentara specializes in statistical and data analysis services for the pharmaceutical and biotechnology sectors, focusing on improving drug development outcomes through innovative study design and analysis [9][10]. Group 3: Strategic Implications - The partnership is expected to enable Pentara to proactively mitigate early risks and implement scalable monitoring of clinical trial sites, enhancing confidence in efficacy outcomes [6]. - NetraMark's AI technology will inform sponsors about potential improvements in trial design, extending beyond participant eligibility to earlier stages like pre-trial site selections [5].

Core Insights - NetraMark Holdings Inc. has entered into a partnership with AlgoTherapeutix SAS to utilize its NetraAI platform for analyzing patient-level data from AlgoTx's ATX01 program, aimed at enhancing clinical trial design for chemotherapy-induced peripheral neuropathy (CIPN) [1][2][3] Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [6] - AlgoTherapeutix is a clinical-stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, specifically targeting chemotherapy-induced peripheral neuropathy with its lead asset, ATX01 [8][9] Partnership Details - The collaboration will leverage NetraAI's technology to explore drug and placebo response variables, identify responder personas, and develop enrichment strategies for future ATX01 trials [2][4] - NetraMark will create customized AI models and interactive tools to assist AlgoTx in testing hypotheses and characterizing patient subpopulations, aiming to generate validated and regulator-ready insights [5][4] Product Information - ATX01 is a proprietary topical formulation of amitriptyline designed to provide targeted relief from pain associated with CIPN, which affects 68% of cancer treatment patients [9][10] - The product has received FDA fast track development status, indicating its potential significance in addressing a high unmet medical need [9] Financial Background - AlgoTx raised EUR 20 million in a Series B funding round in 2023, bringing its total funding to EUR 35 million, supported by a consortium of investors [11]

Core Insights - NetraMark Holdings Inc. has released a preprint demonstrating that its AI platform, NetraAI, significantly outperforms leading large language models like DeepSeek and ChatGPT in analyzing clinical trial data [1][2][3] Study Overview - The study titled "Integrating Dynamical Systems Learning with Foundational Models: A Meta-Evolutionary AI Framework for Clinical Trials" tested NetraAI against DeepSeek, ChatGPT, and traditional machine learning models using complex clinical trial datasets [2][4] - The datasets included CATIE (schizophrenia), CAN-BIND (depression), and COMPASS (pancreatic cancer chemotherapy), known for their complexity and noise [4] Summary of Results - NetraAI was the only AI system able to extract statistically valid, clinically actionable insights from real-world trial data, achieving predictive model performance exceeding 100% accuracy [5] - It identified interpretable patient subgroups and provided clarity where other models generated noise [5] Detailed Trial Comparisons 1. **CATIE Trial Data (Schizophrenia)** - NetraAI produced clear subgroups with minimal variables, improving predictive model performance from 55-66% to over 85% [7] - DeepSeek and ChatGPT failed to generate meaningful outputs, returning generic summaries and random outliers [7] 2. **CAN-BIND Trial Data (Depression)** - NetraAI achieved model accuracy of 91-100% with AUCs nearing 0.99, while traditional ML plateaued at 55-66% accuracy [9] - ChatGPT and DeepSeek delivered no actionable insights and could not identify any subgrouping [9] 3. **COMPASS Trial Data (Pancreatic Cancer Chemotherapy)** - NetraAI identified clinically relevant patient personas with model accuracy of 90-95%, significantly outperforming traditional ML [10] - DeepSeek and ChatGPT produced no clinically interpretable patient subgroups, highlighting their unsuitability for precision oncology applications [10] Unique Features of NetraAI - NetraAI is built on a unique mathematical foundation that integrates dynamical systems theory, evolutionary computation, and information geometry [10][11] - It includes a knowledge-layer strategist that integrates scientific literature, making it purpose-built for clinical trial contexts [11] Importance of NetraAI - The platform addresses the challenge of enrolling the right patients in clinical trials, which is crucial as many trials fail not due to ineffective drugs but because of incorrect patient selection [12] - NetraAI reveals actionable hidden treatment signals that can significantly alter the trajectory of clinical trials [12] Company Background - NetraMark focuses on developing Generative AI and Machine Learning solutions targeted at the pharmaceutical industry, utilizing a novel algorithm to parse patient data into meaningful subsets [14]

Core Insights - NetraMark Holdings Inc. is focused on leveraging AI solutions to enhance clinical trial design in the pharmaceutical industry, as highlighted by a new publication led by founder Dr. Joseph Geraci [1][2][6] - The publication discusses the integration of AI/ML in clinical trials, emphasizing the need for alignment with Good Clinical Practice (GCP) [2][4] - The collaborative effort includes contributions from various regulatory and pharmaceutical organizations, showcasing a broad consensus on the potential of AI/ML in improving clinical trial outcomes [3][4] Group 1: Publication Overview - The manuscript titled "Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Good Clinical Practice Perspectives" is now available in the Journal of the Society for Clinical Data Management [2] - It outlines ideal conditions for AI applications in clinical trials and stresses the importance of compliance, transparency, and patient safety [2][4] - The publication identifies seven real-world use cases where AI can enhance clinical trial effectiveness [4] Group 2: Challenges and Ethical Considerations - The manuscript addresses challenges and ethical considerations in adopting AI/ML in clinical trials, including data quality monitoring and patient stratification [4][5] - Key challenges include data attributability in wearable device data and the need for robust privacy controls [5] - Ethical considerations focus on ensuring AI is lawful, ethical, and socially robust, with an emphasis on explainability and auditability [5] Group 3: Company Commitment and Future Directions - NetraMark is committed to collaborating with sponsors to maximize the benefits of AI/ML in clinical trials, aiming to set industry standards for ethical compliance [6] - The company utilizes a novel topology-based algorithm to analyze patient data, enabling effective segmentation and classification for clinical trials [7] - NetraMark's approach allows for the use of smaller datasets while maintaining accuracy in disease classification and treatment efficacy [7]

Core Insights - NetraMark Holdings Inc. successfully held its Annual General Meeting on June 9, 2025, where all matters presented were approved by shareholders [1] - The company focuses on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry [3] Group 1: Company Developments - Shareholders elected PJ Haley, Dr. Joseph Geraci, George Achilleos, and Andrew Parks as directors, with Andrew Parks appointed as Chairman following the meeting [2] - The company utilizes a novel topology-based algorithm to parse patient data sets into related subsets, enhancing the ability to segment diseases and classify patients for drug sensitivity and treatment efficacy [3] Group 2: Industry Focus - NetraMark aims to transform clinical trial design in the pharmaceutical industry by leveraging its advanced AI and ML capabilities [1][4] - The company's approach allows for effective analysis of smaller datasets, improving the accuracy of disease classification and patient treatment assessments [3]